The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study.
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Bevacizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 03 Jun 2024 Status changed from completed to withdrawn prior to enrolment.
- 17 Oct 2007 Status change from recruting to completed.
- 06 Aug 2007 New trial record.